On 9 October Otonomy, Inc. (NASDAQ:OTIC) announced the enrollment of the first patients in a multiple-dose safety study of OTO-104 initiated in the United Kingdom (U.K.) in patients with Ménière’s disease. Otonomy, Inc. (NASDAQ:OTIC) belongs to Healthcare sector. Its performance is 3.27%. On last trading day company shares ended up $22.43. Otonomy, Inc. (NASDAQ:OTIC) distance from 50-day simple moving average (SMA50) is 9.68%. Priceline Group … Continue reading Top Stories: Otonomy, Inc. (NASDAQ:OTIC), The Priceline Group Inc. (NASDAQ:PCLN), Mechel OAO (NYSE:MTL), Tyson Foods, Inc. (NYSE:TSN), WD-40 Company (NASDAQ:WDFC)